

# NEUROLOGY

**Statin treatment withdrawal in ischemic stroke: A controlled randomized study**  
M. Blanco, F. Nombela, M. Castellanos, M. Rodriguez-Yáñez, M. García-Gil, R. Leira,  
I. Lizasoain, J. Serena, J. Vivancos, M. A. Moro, A. Dávalos and J. Castillo  
*Neurology* 2007;69;904-910  
DOI: 10.1212/01.wnl.0000269789.09277.47

**This information is current as of January 14, 2009**

The online version of this article, along with updated information and services, is  
located on the World Wide Web at:  
<http://www.neurology.org/cgi/content/full/69/9/904>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2007 by AAN Enterprises, Inc. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.



# Statin treatment withdrawal in ischemic stroke

## A controlled randomized study

M. Blanco, MD, PhD  
F. Nombela, MD, PhD  
M. Castellanos, MD, PhD  
M. Rodríguez-Yáñez, MD, PhD  
M. García-Gil, MD, PhD  
R. Leira, MD, PhD  
I. Lizasoain, MD, PhD  
J. Serena, MD, PhD  
J. Vivancos, MD, PhD  
M.A. Moro, PhD  
A. Dávalos, MD, PhD  
J. Castillo, MD, PhD

CME

Address correspondence and reprint requests to Dr. José Castillo, Department of Neurology, Hospital Clínico Universitario, Travesa da Choupana s/n, 15706 Santiago de Compostela, Spain  
mecasti@usc.es

### ABSTRACT

**Background:** Pretreatment with statins has been shown to reduce brain injury in cerebral ischemia. In this controlled randomized study, we investigated the influence of statin pretreatment and its withdrawal on the outcome of acute ischemic stroke patients.

**Methods:** From 215 patients admitted within 24 hours of a hemispheric ischemic stroke, 89 patients on chronic statin treatment were randomly assigned either to statin withdrawal for the first 3 days after admission ( $n = 46$ ) or to immediately receive atorvastatin 20 mg/day ( $n = 43$ ). The primary outcome event was death or dependency (modified Rankin Scale [mRS] score  $> 2$ ) at 3 months. Early neurologic deterioration (END) and infarct volume at days 4 to 7 were secondary outcome variables. In a secondary analysis, outcome variables were compared with the nonrandomized patients without previous statin therapy ( $n = 126$ ).

**Results:** Patients with statin withdrawal showed a higher frequency of mRS score  $> 2$  at the end of follow-up (60.0% vs 39.0%;  $p = 0.043$ ), END (65.2% vs 20.9%;  $p < 0.0001$ ), and greater infarct volume (74 [45, 126] vs 26 [12, 70] mL;  $p = 0.002$ ) compared with the non-statin-withdrawal group. Statin withdrawal was associated with a 4.66 (1.46 to 14.91)-fold increase in the risk of death or dependency, a 8.67 (3.05 to 24.63)-fold increase in the risk of END, and an increase in mean infarct volume of 37.63 mL (SE 10.01;  $p < 0.001$ ) after adjusting for age and baseline stroke severity. Compared with patients without previous treatment with statins, statin withdrawal was associated with a 19.01 (1.96 to 184.09)-fold increase in the risk of END and an increase in mean infarct volume of 43.51 mL (SE 21.91;  $p = 0.048$ ).

**Conclusion:** Statin withdrawal is associated with increased risk of death or dependency at 90 days. Hence, this treatment should be continued in the acute phase of ischemic stroke.

**Neurology**® 2007;69:904-910

There is increasing evidence of the role of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) in the primary and secondary prevention of cardiovascular events.<sup>1,2</sup> In the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study in subjects without previous history of atrial fibrillation or coronary heart disease who had an ischemic stroke or a TIA 1 to 6 months before enrollment in the trial, atorvastatin 80 mg/day was associated with a significant 16% risk reduction of fatal or nonfatal stroke during a 5-year follow-up.<sup>3</sup>

Besides the effect of statin treatment in stroke prevention, recent open reports suggest that statins may have a neuroprotective effect in the acute phase of stroke.<sup>4,5</sup> In addition to a strong cholesterol-lowering effect, statins have a direct influence on endothelial function, inflammatory activity, oxidative stress, blood coagulation, platelet function, cellular proliferation and differentiation, plaque stability, angiogenesis, and the immune

From the Department of Neurology (M.B., M.R.-Y., R.L., J.C.), Hospital Clínico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, Spain; Department of Neurology (F.N., J.V.), Hospital Universitario de La Princesa, Madrid, Spain; Department of Neurology (M.C., J.S.) and Biostatistics Unit (M.G.-G.), Hospital Universitari Doctor Josep Trueta, Girona, Spain; Department of Pharmacology (I.L., M.A.M.), School of Medicine, Universidad Complutense, Madrid, Spain; Department of Neurosciences (A.D.), Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

This project was partially supported by grants from the Spanish Ministry of Health (Instituto de Salud Carlos III) RETICS-RD06/0026.

**Disclosure:** Dr. José Castillo, Dr. José Vivancos, and Dr. Antonio Dávalos are scientific advisors to Pfizer. Dr. Antonio Dávalos is a member of the SPARCL Writing Committee. The rest of the authors report no conflicts of interest.

Partial results of this investigation were presented at the 31st International Stroke Conference in Kissimmee, FL (February 2006).

system.<sup>6</sup> Recent clinical studies also suggest that the acute withdrawal of statin treatment has deleterious effects on vascular function<sup>7,8</sup> and brain injury.<sup>9</sup>

Discontinuation of oral intake during the first days of an acute stroke, which may include chronic therapy with drugs such as statins, is a practice to avoid the risk of bronchoaspiration, particularly in the most severe strokes; therefore, it is crucial to evaluate the potential harmful effect of this *modus operandi*. The aim of this open, controlled, randomized study was to investigate the effect on functional outcome of previous statin treatment and its withdrawal after the onset of symptoms in patients with acute ischemic stroke.

**METHODS** **Study design.** This controlled randomized study was conducted from October 2003 to May 2005 at a single center. Consecutive patients with acute hemispheric ischemic stroke admitted within the first 24 hours after onset of symptoms were studied. Reasons for exclusion were chronic inflammatory, infectious, or hematologic diseases; cancer; renal or liver failure; treatment with corticoids or antiinflammatory drugs in the week before stroke; acute treatment with fibrinolytic or investigational drugs; and life expectancy of less than 6 months. The absence of dysphagia was not an exclusion criterion because, when this study was designed, neither statin treatment nor statin withdrawal in the acute phase of stroke had previously shown beneficial or harmful effects in controlled studies. Accordingly, the local ethics committee approved the study, and informed consent was obtained from either the patients or their relatives.

**Study intervention.** Those patients who were receiving statins before admission were randomly assigned to interrupt this treatment for the first 3 days of hospitalization (statin-withdrawal group) or to immediately receive atorvastatin orally (or through a nasogastric tube) at a dose of 20 mg daily (non-statin-withdrawal group), regardless of the drug and dosage the patient had previously received. Patients were assigned to one group or the other depending on whether their date of admission fell on an odd or an even day. Patients who did not receive statins before admission were followed up as a reference group for secondary analyses. From the fourth day onward, atorvastatin 20 mg daily was also administered in patients who were randomly assigned to statin withdrawal and in those who were not on previous statin treatment. All patients were discharged on treatment with 20 mg of atorvastatin daily. The statin treatment was continued at least 3 months.

Patients were treated in an acute stroke unit following the guidelines of the Study Group for Cerebrovascular Diseases of the Spanish Neurological Society.<sup>10</sup> Transcranial Doppler and carotid ultrasound studies were performed on all patients, whereas echocardiography and magnetic resonance angiography or conventional angiography were performed on selected patients. Stroke subtype was classified as atherothrombotic, cardioembolic, small vessel disease, or cryptogenic.<sup>11</sup>

**Clinical and radiologic assessment.** The NIH Stroke Scale (NIHSS) score was measured on admission, every 24 hours throughout the period of hospitalization, and at 3 months of follow-up by a certified neurologist. Early neurologic deterioration (END) was defined as an increase of  $\geq 4$  points in the NIHSS score between admission and any time during the first 48 hours of hospitalization.

Neuroimaging assessment included a brain MRI with diffusion-weighted imaging, fluid-attenuated inversion recovery, and T2 sequences performed on admission, and a cranial CT performed between the fourth and seventh day after onset of symptoms. Infarct volume was measured on the CT study using a manual tracing method.


The primary outcome event was death or dependency evaluated at 3 months by using the modified Rankin Scale (mRS). Dependency was defined as an mRS score  $> 2$ . Secondary outcomes were END and infarct volume. All CT evaluations and mRS score assessments were performed by investigators who were blinded to the randomization and treatment during the acute phase.

**Statistical analysis.** The sample size was chosen to provide 90% power and a level of significance of 5% in a unilateral contrast to detect a common odds ratio (OR) for decrease of dependency at 90 days of 4.0, according to the lowest 95% CI observed in a previous retrospective nonrandomized study. Based on these previous data, we assumed a proportion of patients with poor outcome in the non-statin-withdrawal group of 36%.<sup>9</sup>

Results are expressed as percentages for categorical variables and compared using the chi-square test, and as mean (SD), or median [quartiles] for the continuous variables and compared using Student's *t* test or the Mann-Whitney test, depending on whether they were normally distributed. The influence of statin withdrawal on the primary outcome event and on END was evaluated using logistic regression analysis. The Spearman correlation coefficient was used to analyze the association between infarct volume and baseline continuous variables. Generalized linear models were used to assess the influence of statin withdrawal on infarct volume. For the primary analysis, which was performed comparing the groups of randomized patients, models were adjusted for age and the severity of neurologic deficit on admission. In a secondary analysis, primary and secondary outcome variables in the statin-withdrawal group were compared with those of nonrandomized patients who were not on previous statin therapy ( $n = 126$ ). For the secondary analysis, logistic regression and lineal models were adjusted for age, severity of neurologic deficit at admission, and those variables that were differently distributed between the groups ( $p < 0.05$ ). We fitted the models in a customized way by means of the Enter method. Values of *p* below 0.05 were considered to be significant in all tests.

**RESULTS** **Baseline patient characteristics and treatment allocation.** Three-hundred fourteen patients were considered for inclusion in the study. Twenty-one patients randomized in clinical trials with drugs under investigation, 27 patients treated with fibrinolysis, 13 patients with chronic inflammatory processes and/or treatment with corticoids or anti-inflammatory drugs in the week before stroke, 31 patients with comorbidity and

**Figure 1** Classification of patients included in the study



life expectancy of less than 6 months, and 7 patients in whom the diagnosis of stroke could not be confirmed were excluded; thus, 215 patients [53% men, 68.8 (11.1) years] were valid for the analysis. The median time from the onset of symptoms to inclusion was 6 [3.5, 11.5] hours. Eighty-nine patients who were receiving statins before stroke onset (median duration of chronic statin treatment, 8.7 [2, 34] months) were randomly assigned to withdraw statins ( $n = 46$ ) or to receive 20 mg/day of atorvastatin for 3 days ( $n = 43$ ) (figure 1). As expected, the two groups were comparable regarding baseline vascular risk factors, clinical characteristics, and stroke subtype (table 1).

**Primary outcome event.** Three patients who completed the study during hospitalization were lost to follow-up at 3 months, 1 in the statin-withdrawal group and 2 in the non-statin-withdrawal group. Twenty-seven patients (60%) in the statin-withdrawal group and 16 (39%) in the non-statin-withdrawal group were dead or dependent at the end of the study period ( $p = 0.043$ ). The adjusted and unadjusted ORs of the effect of statin withdrawal on the primary outcome variable are shown in table 2. Statin with-

**Table 1** Baseline vascular risk factors, clinical characteristics, biochemical variables, and stroke subtype in patients with and without statin withdrawal

|  | Statin-withdrawal group, $n = 46$ | Non-statin-withdrawal group, $n = 43$ | $p$ Value |
|--|-----------------------------------|---------------------------------------|-----------|
| Age, years                                 | 66.5 (11.8)                       | 67.9 (13.1)                           | 0.580     |
| Stroke onset to inclusion, hours           | 6.5 [3.8, 14.6]                   | 5 [3.5, 10]                           | 0.249     |
| Men, $n$ (%)                               | 22 (47.8)                         | 23 (53.5)                             | 0.673     |
| History of hypertension, $n$ (%)           | 29 (63.0)                         | 23 (53.8)                             | 0.396     |
| History of diabetes, $n$ (%)               | 16 (34.8)                         | 16 (37.2)                             | 0.829     |
| History of atrial fibrillation, $n$ (%)    | 7 (15.2)                          | 5 (11.6)                              | 0.759     |
| History of dyslipemia, $n$ (%)             | 46 (100)                          | 40 (93)                               | 0.109     |
| Systolic blood pressure, mm Hg             | 160.9 (34.7)                      | 161.8 (32.2)                          | 0.899     |
| Diastolic blood pressure, mm Hg            | 89.4 (20.3)                       | 88.6 (20.9)                           | 0.858     |
| Axillary temperature on admission, °C      | 37.0 (0.7)                        | 37.1 (0.7)                            | 0.680     |
| NIHSS score on admission                   | 12 [8, 18]                        | 14 [10, 18]                           | 0.523     |
| Leukocytes on admission, $\times 10^3$ /dL | 6.3 (1.9)                         | 6.2 (2.0)                             | 0.832     |
| Blood glucose on admission, mg/dL          | 156.1 (51.2)                      | 168.5 (83.5)                          | 0.406     |
| Total cholesterol, mg/dL                   | 258.7 (2.3)                       | 261.8 (3.1)                           | 0.674     |
| LDL cholesterol, mg/dL                     | 179.6 (2.1)                       | 182.1 (3.9)                           | 0.706     |
| Etiological diagnosis, $n$ (%)             |                                   |                                       | 0.965     |
| Atherothrombotic                           | 27 (58.7)                         | 23 (53.3)                             |           |
| Cardioembolic                              | 9 (19.6)                          | 10 (23.3)                             |           |
| Lacunar                                    | 8 (17.4)                          | 8 (18.6)                              |           |
| Cryptogenic                                | 2 (4.3)                           | 2 (4.7)                               |           |

NIHSS = NIH Stroke Scale; LDL = low-density lipoprotein.

**Table 2** Unadjusted and adjusted ORs of death or dependency and END in patients with and without statin withdrawal

|                                | Statin-withdrawal group, n (%) | Non-statin-withdrawal group, n (%) | OR (95% CI)        | Adjusted OR (95% CI)* |
|--------------------------------|--------------------------------|------------------------------------|--------------------|-----------------------|
| Primary outcome event*         | 27 (60.0)                      | 16 (39.0)                          | 2.39 (1.02, 5.62)  | 4.66 (1.46, 14.91)    |
| Early neurologic deterioration | 30 (65.2)                      | 9 (20.9)                           | 7.08 (2.73, 18.37) | 8.67 (3.05, 24.63)    |

\* Adjusted by age and NIH Stroke Scale score at admission

\* Death or dependency (modified Rankin Scale score > 2) was evaluated at 3 months in 45 patients of the statin-withdrawal group and in 41 patients of the non-statin-withdrawal group. OR = odds ratio; END = early neurologic deterioration.

drawal was associated with a significant increase in the risk of death or dependency, which was even higher after adjustment for age and stroke severity at admission (OR 4.66; 95% CI 1.46 to 14.91).

**Secondary outcome variables.** END was found in 30 patients (65.2%) of the statin-withdrawal group and in 9 patients (20.9%) of the non-statin-withdrawal group ( $p < 0.0001$ ). Statin withdrawal was associated with an increase in the risk of END (unadjusted OR 7.08; 95% CI 2.73 to 18.37;  $p < 0.001$ ), which was not substantially modified after adjustment for age and stroke severity (table 2).

Infarct volume was greater in the group of patients with statin withdrawal compared with the non-statin-withdrawal group (74, 45, 126 vs 26, 12, 70 mL;  $p = 0.002$ ) (figure 2). After adjusting for age and NIHSS score at admission, the withdrawal of statins was found to be associated with greater enlargement of the infarct volume, because this factor yielded an estimated mean increase in infarct volume of 37.63 mL (SE 10.01;  $p < 0.001$ ).

**Secondary analysis.** Patients of the reference group showed a higher frequency of atrial fibrillation (31% vs 13.1%;  $p = 0.003$ ) and lower frequency of previous history of hypercholesterolemia


(2.4% vs 96.6%;  $p < 0.0001$ ) than the randomized patients. No other significant differences were found in the distribution of the baseline characteristics between the groups.

A  $2 \times 2$  secondary post hoc analysis showed no differences in the percentage of patients with the primary outcome event between the statin-withdrawal group and the reference group of patients who had not been on previous treatment with statins (58.7% vs 42.1%;  $p = 0.059$ ), but the statistical power to detect differences was of 26%. The proportion of patients with END was higher in the statin-withdrawal group (65.2% vs 27.8%;  $p < 0.0001$ ). Compared with patients without previous treatment with statins, statin withdrawal was associated with a 19.01 (1.96 to 184.09)-fold increase in the risk of END after adjusting for potential confounders (table 3).

Regarding infarct volume, the  $2 \times 2$  secondary post hoc analysis showed no differences between the group with statin withdrawal and the reference group (74 [45.5, 126.2] vs 53 [14, 117.2] mL;  $p = 0.056$ ). However, statin withdrawal was associated with an estimated mean increase in infarct volume of 43.51 mL (SE 21.91;  $p = 0.048$ ) after adjusting for covariates (table 4).

There was no significant interaction between the effect of statin withdrawal and those factors associated with the outcome variables, indicating that the risk of withdrawing the treatment cannot be attributed to any particular subgroup.

**Figure 2** Infarct volume by groups



Box plots show median values (horizontal line inside the box), quartiles (box boundaries), and the largest and smallest observed values (lines drawn from the end of the box) of infarct volume evaluated on days 4 through 7 of evolution.

**DISCUSSION** The present study shows that the withdrawal of statin therapy immediately after stroke onset is associated with a 4.7-fold increase in the risk of death or dependency at 3 months in comparison with the statin continuation policy. Importantly, the effect on the primary outcome variable is supported by a deleterious effect of statin withdrawal on secondary outcome variables; patients who were allocated to withdrawn statins had an 8.7-fold increase of END and larger infarct volume.

Retrospective studies have shown the benefit



**Table 3** Adjusted ORs of END in patients with and without statin withdrawal comparing with the reference group

|  | OR    | 95% CI         | p Value |
|--|-------|----------------|---------|
| Age                                      | 0.96  | (0.93, 0.98)   | 0.004   |
| NIHSS score at admission                 | 1.09  | (1.03, 1.14)   | 0.001   |
| Previous history of atrial fibrillation  | 1.18  | (0.54, 2.55)   | 0.676   |
| Previous history of dyslipemia           | 0.24  | (0.03, 2.04)   | 0.189   |
| Statin administration in the acute phase |       |                |         |
| Reference group                          | 1.00  |                |         |
| Statin-withdrawal group                  | 19.01 | (1.96, 184.09) | 0.011   |
| Non-statin-withdrawal group              | 1.81  | (0.22, 14.66)  | 0.579   |

OR = odds ratio; END = early neurologic deterioration; NIHSS = NIH Stroke Scale.

of previous long-term statin treatment in improving the prognosis of ischemic stroke,<sup>4,5,12</sup> and preliminary data from a prospective pilot study have suggested the usefulness of initiating statin treatment within the first 12 hours after ischemic stroke onset.<sup>13</sup> However, cardiologic studies seem to show a greater efficacy in those patients who have been pretreated with statins than in those only receiving statins after the onset of acute myocardial infarction.<sup>14</sup>

Experimental models of focal cerebral ischemia and data from several clinical trials have demonstrated that the neuroprotective effect of statins is related not only to the reduction of plasma cholesterol levels but rather to direct effects on endothelial function as well as antithrombotic and anti-inflammatory effects.<sup>6,15-18</sup> Likely, the pleiotropic effects of statins associated to their neuroprotective actions in the acute phase of stroke are related to the overexpression of the endothelial nitric oxide synthase,<sup>19-20</sup> which results

in an improvement of the endothelial function<sup>21-22</sup> as well as in a reduction in thrombogenesis,<sup>23</sup> and an increase in the expression of tissue plasminogen activator.<sup>24</sup> Statins also reduce the levels of proinflammatory cytokines and decrease the expression of adhesion molecules<sup>25</sup>; in fact, in the Cholesterol and Recurrent Events (CARE) study, a reduction in the levels of C-reactive protein has been reported.<sup>26</sup> In this context, and given the greater prominence of cytotoxic effects after cerebral ischemia, it is not surprising that statin withdrawal has a deleterious effect on the prognosis of ischemic stroke patients.

Indeed, in the past few years, several studies have questioned the withdrawal effect after discontinuation of statin therapy, particularly in increasing the risk of recurrent coronary events,<sup>27,28</sup> although all studies have consistently shown increased in-hospital mortality.<sup>14,27,29,30</sup> It has been demonstrated that discontinuation of statin treatment abrogates stroke protection in animal models of ischemia,<sup>31</sup> and it has been also reported in a clinical retrospective study the association between statin withdrawal, poor functional outcome, and larger brain injury in patients with acute atherothrombotic ischemic stroke.<sup>9</sup> Importantly, the present findings indicate that statin withdrawal not only suppresses brain protection of previous treatment but causes deleterious effects in comparison with the lack of statin-linked protection at stroke onset; the rate of END and infarct volume were greater in the statin-withdrawal group than in the reference group. In this context, there is evidence suggesting that acute withdrawal of statin treatment impairs vascular function and triggers a proinflammatory and prothrombotic response.<sup>32-34</sup> Of note, the suppression of endothelial nitric oxide (NO) production,<sup>31</sup> which is mediated by a negative feedback regulation of Rho guanosine triphosphatase gene

**Table 4** Influence of statin administration in the acute phase of stroke on infarct volume in patients with and without statin withdrawal compared with the reference group

|  | $\beta$ | SE    | p Value |
|--|---------|-------|---------|
| Age                                      | -1.16   | 0.31  | <0.001  |
| NIHSS at admission                       | 5.60    | 0.52  | <0.001  |
| Previous history of atrial fibrillation  | -12.30  | 8.19  | 0.135   |
| Previous history of dyslipemia           | 30.15   | 20.66 | 0.146   |
| Statin administration in the acute phase |         |       |         |
| Reference group                          | 1.00    |       |         |
| Statin-withdrawal group                  | 43.51   | 21.91 | 0.048   |
| Non-statin-withdrawal group              | 3.60    | 20.67 | 0.862   |

NIHSS = NIH Stroke Scale.

transcription, might account for this deleterious effect.<sup>35</sup> These actions may explain the harmful rebound phenomenon of statin withdrawal.

Our study has a number of limitations. First, cholesterol levels were not repeatedly measured during the acute phase of stroke. Although the statin-related NO generation is independent of the cholesterol levels,<sup>36</sup> other neuroprotective effects may be related to the degree of lipid levels reduction.<sup>37</sup> A controversial aspect may be the dose of atorvastatin administered in this study. A dose of 80 mg daily has recently shown efficacy in stroke prevention<sup>38</sup>; however, doses between 10 and 20 mg of atorvastatin had been associated with a better outcome in retrospective studies of patients with acute stroke.<sup>5</sup> Although the optimal dose for the acute phase protection of stroke is unknown, this effect of statins likely seems to appear with low doses, because neuroprotection has been demonstrated after the administration of a single dose in animal models of cerebral ischemia.<sup>39</sup>

Our findings strongly support that previous statin therapy should not be interrupted during the acute phase of ischemic stroke. The recommendation to start on statin treatment as soon as ischemic stroke occurs needs to be investigated in further randomized clinical trials.

Received December 27, 2006. Accepted in final form March 29, 2007.

## REFERENCES

1. Amarenco P, Lavallée P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. *Lancet Neurol* 2004;3:271–278.
2. Ovbiagele B, Kidwell CS, Saver JL. Expanding indications for statins in cerebral ischemia: a quantitative study. *Arch Neurol* 2005;62:67–72.
3. The Stroke Prevention by Aggressive Reduction in cholesterol levels (SPARCL) Investigators. High dose atorvastatin after stroke or transient ischaemic attack. *N Engl J Med* 2006;355:549–559.
4. Greisenegger S, Mullner M, Tentschert S, Lang W, Laluschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. *J Neurol Sci* 2004;221:1–2.
5. Martí-Fàbregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. *Stroke* 2004;35:1117–1123.
6. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. *J Atheroscler Thromb* 2004;11:253–264.
7. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. *Lancet* 2000;355:3104–3110.
8. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. *Circulation* 2002;105:1446–1452.
9. Vivancos J, Moro MA, Nombela F, et al. Statins withdrawal is associated with poor outcome in acute atherothrombotic hemispheric ischemic stroke. *Cerebrovasc Dis* 2004;17 (suppl 5):107.
10. Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Guía para el diagnóstico y tratamiento del ictus. Barcelona: Prous Science, 2004.
11. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 1993;24:35–41.
12. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. *Neurology* 2005;65:253–258.
13. Montaner J, Chacón P, Krupinski J, et al. Safety and efficacy of statins in the acute phase of ischemic stroke: the MISTIC trial. *Stroke* 2004;35:293.
14. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. *Am J Cardiol* 2005;96:611–616.
15. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. *Stroke* 1997;28:2315–2320.
16. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. *Circulation* 2000;101:207–213.
17. Sepien K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. *Pharmacol Rep* 2005;57:561–569.
18. Endres M. Statins and stroke. *J Cereb Blood Flow Metab* 2005;25:1093–1110.
19. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest* 1998;101:2711–2719.
20. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. *Proc Natl Acad Sci USA* 1998;95:8880–8885.
21. Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. *Semin Vasc Med* 2004;4:385–393.
22. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. *Circulation* 2004;110:1933–1939.
23. Cha JK, Yeong MH, Kim JW. Statin reduces the platelet P-selectin expression in atherosclerotic ischemic stroke. *J Thromb Thrombolysis* 2004;18:39–42.
24. Asahi M, Huang Z, Thomas S, et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. *J Cereb Blood Flow Metab* 2005;25:722–729.

25. Yoshida M. Potential role of statins in inflammation and atherosclerosis. *J Atheroscler Thromb* 2003;10:140–144.
26. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol independent effects. *Eur Heart J* 2002;23:1908–1921.
27. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. *Circulation* 2002;105:1446–1452.
28. McGowan MP, for the Treating to New Target (TNT) Study Group. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. *Circulation* 2004;110:2333–2335.
29. Spencer FA, Allogrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. *Ann Intern Med* 2004;140:857–866.
30. Spencer FA, Fonarow GC, Frederick PD, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction. National Registry of Myocardial Infarction. *Arch Intern Med* 2004;164:2162–2168.
31. Getz K, Laufs U, Lindaver U, et al. Withdrawal of statin treatment abrogator stroke protection in mice. *Stroke* 2003;34:551–557.
32. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. *Circ Res* 2002;91:173–179.
33. Li J-J, Li Y-S, Chen J, Yang J-Q. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. *Med Hypotheses* 2006;66:1199–1204.
34. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. *Lancet* 2000;354:3104–3110.
35. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of Rho GTPase gene transcription. *Circulation* 2000;102:3104–3110.
36. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. *J Am Coll Cardiol* 1999;33:234–242.
37. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. *Arterioscler Thromb Vasc Biol* 2002;22:1745–1750.
38. La Rosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352:1425–1435.
39. Cimino M, Balduini W, Carloni S, et al. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. *Neurotoxicology* 2005;26:929–933.

## AAN Fall Conference in Las Vegas Presents New Courses, Dystonia Workshop

If you missed the AAN Annual Meeting and need to earn CME credits, reserve the weekend of November 2 through 4, 2007, for the AAN Fall Conference in Las Vegas. Neurologists, nurses, and practice managers can enjoy learning from leading experts in a small-group setting. In addition, new practice management courses will be structured in basic and advanced segments. A Dystonia Workshop also will be offered on November 2. Early registration deadline is October 12, 2007. Visit [www.aan.com/fall07](http://www.aan.com/fall07) for more information about the programs and early registration discount.



**Statin treatment withdrawal in ischemic stroke: A controlled randomized study**  
M. Blanco, F. Nombela, M. Castellanos, M. Rodriguez-Yáñez, M. García-Gil, R. Leira,  
I. Lizasoain, J. Serena, J. Vivancos, M. A. Moro, A. Dávalos and J. Castillo

*Neurology* 2007;69:904-910

DOI: 10.1212/01.wnl.0000269789.09277.47

**This information is current as of January 14, 2009**

|   |  |
|---|--|
| <b>Updated Information &amp; Services</b> | including high-resolution figures, can be found at:<br><a href="http://www.neurology.org/cgi/content/full/69/9/904">http://www.neurology.org/cgi/content/full/69/9/904</a>   |
| <b>Subspecialty Collections</b>           | This article, along with others on similar topics, appears in the following collection(s):<br><b>All Cerebrovascular disease/Stroke</b><br><a href="http://www.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke">http://www.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke</a><br><b>Infarction</b><br><a href="http://www.neurology.org/cgi/collection/infarction">http://www.neurology.org/cgi/collection/infarction</a> |
| <b>Permissions &amp; Licensing</b>        | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:<br><a href="http://www.neurology.org/misc/Permissions.shtml">http://www.neurology.org/misc/Permissions.shtml</a>  |
| <b>Reprints</b>                           | Information about ordering reprints can be found online:<br><a href="http://www.neurology.org/misc/reprints.shtml">http://www.neurology.org/misc/reprints.shtml</a>  |

